Researchers have found that a combination of mesenchymal-epithelial transition and the AXL inhibitor TP-0903 can make triple-negative breast cancer cells more sensitive to the antimalarial compound artesunate. This discovery suggests a potential new approach to treating this type of cancer. The role of AXL and epithelial-mesenchymal transition in cancer is an area of ongoing research, with multiple studies exploring their involvement in cancer development and potential therapeutic targets.